Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 261

1.

3D Imaging Detection of HER2 Based in the Use of Novel Affibody-Quantum Dots Probes and Ratiometric Analysis.

Pérez-Treviño P, la Cerda HH, Pérez-Treviño J, Fajardo-Ramírez OR, García N, Altamirano J.

Transl Oncol. 2018 Apr 4;11(3):672-685. doi: 10.1016/j.tranon.2018.03.004. [Epub ahead of print]

2.

Using in vivo fluorescence lifetime imaging to detect HER2-positive tumors.

Ardeshirpour Y, Sackett DL, Knutson JR, Gandjbakhche AH.

EJNMMI Res. 2018 Apr 4;8(1):26. doi: 10.1186/s13550-018-0384-6.

3.

Site-Specific Photoconjugation of Beta-Lactamase Fragments to Monoclonal Antibodies Enables Sensitive Analyte Detection via Split-Enzyme Complementation.

Yu F, Alesand V, Nygren PÅ.

Biotechnol J. 2018 Feb 27. doi: 10.1002/biot.201700688. [Epub ahead of print]

PMID:
29485240
4.

Radionuclide therapy of HER2-expressing human xenografts using an affibody molecule-based PNA-mediated pretargeting: in vivo proof-of-principle.

Westerlund K, Altai M, Mitran B, Konijnenberg M, Oroujeni M, Atterby C, de Jong M, Orlova A, Mattsson J, Micke P, Eriksson Karlström A, Tolmachev V.

J Nucl Med. 2018 Feb 9. pii: jnumed.118.208348. doi: 10.2967/jnumed.118.208348. [Epub ahead of print]

PMID:
29439013
5.

HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.

Martins CD, Da Pieve C, Burley TA, Smith R, Ciobota DM, Allott L, Harrington KJ, Oyen WJG, Smith G, Kramer-Marek G.

Clin Cancer Res. 2018 Apr 15;24(8):1853-1865. doi: 10.1158/1078-0432.CCR-17-2754. Epub 2018 Feb 6.

PMID:
29437790
6.

Genetically Engineered Liposome-like Nanovesicles as Active Targeted Transport Platform.

Zhang P, Zhang L, Qin Z, Hua S, Guo Z, Chu C, Lin H, Zhang Y, Li W, Zhang X, Chen X, Liu G.

Adv Mater. 2018 Feb;30(7). doi: 10.1002/adma.201705350. Epub 2017 Dec 27.

PMID:
29280210
7.

Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with <sup>64</sup>Cu Using NOTA and NODAGA.

Tolmachev V, Yim CB, Rajander J, Perols A, Karlström AE, Haaparanta-Solin M, Grönroos TJ, Solin O, Orlova A.

Contrast Media Mol Imaging. 2017 Feb 28;2017:8565802. doi: 10.1155/2017/8565802. eCollection 2017.

8.

Al18F-Labeling Of Heat-Sensitive Biomolecules for Positron Emission Tomography Imaging.

Cleeren F, Lecina J, Ahamed M, Raes G, Devoogdt N, Caveliers V, McQuade P, Rubins DJ, Li W, Verbruggen A, Xavier C, Bormans G.

Theranostics. 2017 Jul 14;7(11):2924-2939. doi: 10.7150/thno.20094. eCollection 2017.

9.

Evaluation of affibody molecule-based PNA-mediated radionuclide pretargeting: Development of an optimized conjugation protocol and <sup>177</sup>Lu labeling.

Altai M, Westerlund K, Velletta J, Mitran B, Honarvar H, Karlström AE.

Nucl Med Biol. 2017 Nov;54:1-9. doi: 10.1016/j.nucmedbio.2017.07.003. Epub 2017 Jul 12.

PMID:
28810153
10.

Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1.

Sochaj-Gregorczyk AM, Ludzia P, Kozdrowska E, Jakimowicz P, Sokolowska-Wedzina A, Otlewski J.

Int J Mol Sci. 2017 Aug 3;18(8). pii: E1688. doi: 10.3390/ijms18081688.

11.

PET of HER2 Expression with a Novel <sup>18</sup>FAl Labeled Affibody.

Xu Y, Bai Z, Huang Q, Pan Y, Pan D, Wang L, Yan J, Wang X, Yang R, Yang M.

J Cancer. 2017 Apr 9;8(7):1170-1178. doi: 10.7150/jca.18070. eCollection 2017.

13.

Specific targeting of HER2-positive head and neck squamous cell carcinoma line HN5 by Idarubicin-ZHER2 affibody conjugate.

Ghanemi M, Pourshohod A, Ghaffari MA, Kheirollah A, Amin M, Zeinali M, Jamalan M.

Curr Cancer Drug Targets. 2017 Apr 26. doi: 10.2174/1568009617666170427105417. [Epub ahead of print]

PMID:
28460618
14.

Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.

Sandberg D, Tolmachev V, Velikyan I, Olofsson H, Wennborg A, Feldwisch J, Carlsson J, Lindman H, Sörensen J.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1337-1346. doi: 10.1007/s00259-017-3650-3. Epub 2017 Mar 6.

15.

Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells.

Schardt JS, Oubaid JM, Williams SC, Howard JL, Aloimonos CM, Bookstaver ML, Lamichhane TN, Sokic S, Liyasova MS, O'Neill M, Andresson T, Hussain A, Lipkowitz S, Jay SM.

Mol Pharm. 2017 Apr 3;14(4):1047-1056. doi: 10.1021/acs.molpharmaceut.6b00919. Epub 2017 Mar 8.

16.

A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.

Serwotka-Suszczak AM, Sochaj-Gregorczyk AM, Pieczykolan J, Krowarsch D, Jelen F, Otlewski J.

Int J Mol Sci. 2017 Feb 14;18(2). pii: E401. doi: 10.3390/ijms18020401.

17.

Targeted delivery of an ADP-ribosylating bacterial toxin into cancer cells.

Zahaf NI, Lang AE, Kaiser L, Fichter CD, Lassmann S, McCluskey A, Augspach A, Aktories K, Schmidt G.

Sci Rep. 2017 Jan 27;7:41252. doi: 10.1038/srep41252.

18.

Multifunctional Conjugated Polymer Nanoparticles for Image-Guided Photodynamic and Photothermal Therapy.

Feng G, Fang Y, Liu J, Geng J, Ding D, Liu B.

Small. 2017 Jan;13(3). doi: 10.1002/smll.201602807. Epub 2016 Nov 7.

PMID:
28084693
19.

Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo.

Mohamed Suffian IFB, Wang JT, Hodgins NO, Klippstein R, Garcia-Maya M, Brown P, Nishimura Y, Heidari H, Bals S, Sosabowski JK, Ogino C, Kondo A, Al-Jamal KT.

Biomaterials. 2017 Mar;120:126-138. doi: 10.1016/j.biomaterials.2016.12.012. Epub 2016 Dec 14.

20.

DNA-affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2.

Zhang Y, Jiang S, Zhang D, Bai X, Hecht SM, Chen S.

Chem Commun (Camb). 2017 Jan 3;53(3):573-576. doi: 10.1039/c6cc08495h.

PMID:
27975087

Supplemental Content

Loading ...
Support Center